{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:13Z","timestamp":1792806193151,"version":"4.5.0"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University","award":["WSUB\/2023\/07\/00009"],"award-info":[{"award-number":["WSUB\/2023\/07\/00009"]}],"id":[{"id":"https:\/\/ror.org\/03m9nwf24","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Targeted therapies represent major advancements in the treatment of chronic skin conditions such as psoriasis. While previous studies have shown an increased risk of melanoma and non-melanoma skin cancer (NMSC) in patients receiving TNF-\u03b1 inhibitors, the risks associated with newer biologics (IL-12\/23 inhibitors, IL-23 inhibitors, IL-17 inhibitors) and Janus kinase (JAK) inhibitors remain less known. Using a systematic and meta-analytical approach, we aimed to summarize the currently available literature concerning skin cancer risk in patients treated with targeted therapies. The MEDLINE\/PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched to find studies reporting the incidence rates (IR) of melanoma and NMSC in patients with psoriasis and psoriatic arthritis treated with biologics or JAK inhibitors. Nineteen studies were included in the analysis with a total of 13,739 patients. The overall IR of melanoma was 0.08 (95% CI, 0.05\u20130.15) events per 100 PYs and the overall IR of NMSC was 0.45 (95% CI, 0.33\u20130.61) events per 100 PYs. The IRs of melanoma were comparable across patients treated with IL-17 inhibitors, IL-23 inhibitors, and JAK inhibitors, while the IRs of NMSC were higher in patients treated with JAK inhibitors than in those treated with biologics. Prospective, long-term cohort studies are required to reliably assess the risks associated with novel targeted therapies.<\/jats:p>","DOI":"10.3390\/ph17010014","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T08:16:02Z","timestamp":1703146562000},"page":"14","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-2722","authenticated-orcid":false,"given":"Marta","family":"Krzysztofik","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, 31-913 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Brzewski","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, 31-913 Krakow, Poland"},{"name":"Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Cuber","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland"},{"name":"Department of Oncological Surgery, 5th Military Clinical Hospital in Krak\u00f3w, 30-901 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Kacprzyk","sequence":"additional","affiliation":[{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-530 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-4242","authenticated-orcid":false,"given":"Aleksandra","family":"Kulbat","sequence":"additional","affiliation":[{"name":"Department of Oncological Surgery, 5th Military Clinical Hospital in Krak\u00f3w, 30-901 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Richter","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wojewoda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland"},{"name":"Department of Oncological Surgery, 5th Military Clinical Hospital in Krak\u00f3w, 30-901 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-3220","authenticated-orcid":false,"given":"Wojciech M.","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, Poland"},{"name":"Department of Oncological Surgery, 5th Military Clinical Hospital in Krak\u00f3w, 30-901 Krakow, Poland"},{"name":"National Institute of Oncology, Maria Sk\u0142odowska-Curie Memorial, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A Systematic Review of Worldwide Epidemiology of Psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational and Clinical Studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1067\/mjd.2001.114576","article-title":"The Risk of Melanoma in Association with Long-Term Exposure to PUVA","volume":"44","author":"Stern","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/bjd.15170","article-title":"Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma: A Retrospective Comparative Registry-Based Cohort Study","volume":"176","author":"Polesie","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of Malignancy with Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12935-021-02325-9","article-title":"Risk of Non-Melanoma Skin Cancer with Biological Therapy in Common Inflammatory Diseases: A Systemic Review and Meta-Analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_10","unstructured":"Wells, G., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2000). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses, Ottawa Hospital."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the Metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Spittal, M.J., Pirkis, J., and Gurrin, L.C. (2015). Meta-Analysis of Incidence Rate Data in the Presence of Zero Events. BMC Med. Res. Methodol., 15.","DOI":"10.1186\/s12874-015-0031-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying Heterogeneity in a Meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13075-023-03078-8","article-title":"Response to Treatment in Psoriatic Arthritis, the Effect of Age: Analysis of Patients Receiving Ustekinumab in the PsABio Real-World Study","volume":"25","author":"Gossec","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy Rates through 5 Years of Follow-up in Patients with Moderate-to-Severe Psoriasis Treated with Guselkumab: Pooled Results from the VOYAGE 1 and VOYAGE 2 Trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug. Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials","volume":"9","author":"Burmester","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results through One Year of a Phase IIIb, Randomised, Controlled Study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.42280","article-title":"Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: Three-Year Results from a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study","volume":"74","author":"Coates","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety Results of Ixekizumab with 1822.2 Patient-Years of Exposure: An Integrated Analysis of 3 Clinical Trials in Adult Patients with Psoriatic Arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of Subcutaneous Secukinumab 150 Mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the KEEPsAKE 1 Study","volume":"62","author":"Kristensen","year":"2023","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40257-019-00466-2","article-title":"Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study","volume":"20","author":"Lebwohl","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab Sustains Improvement in Signs and Symptoms of Psoriatic Arthritis: 2 Year Results from the Phase 3 FUTURE 2 Study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Na\u00efve Patients with Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s13555-022-00776-0","article-title":"Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation","volume":"12","author":"Odnopozova","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","article-title":"Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the KEEPsAKE 2 Study","volume":"62","author":"Papp","year":"2023","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results from 2 Randomized Phase-III Studies and 1 Open-Label Long-Term Extension Study","volume":"74","author":"Papp","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-label Extension Trial beyond 3 Years of Follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year Efficacy and Safety of Tildrakizumab in Patients with Moderate-to-severe Psoriasis Who Respond at Week 28: Pooled Analyses of Two Randomized Phase III Clinical Trials (ReSURFACE 1 and ReSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"687432","DOI":"10.3389\/fonc.2021.687432","article-title":"Incidence of Skin Cancer in Patients with Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies","volume":"11","author":"Crisafulli","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_35","unstructured":"Centers for Disease Control and Prevention (2018). United States Cancer Statistics: Incidence of Malignant Melanoma of the Skin\u2014United States, 2009\u20132018, USCS Data Brief, No. 28."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hu, W., Fang, L., Ni, R., Zhang, H., and Pan, G. (2022). Changing Trends in the Disease Burden of Non-Melanoma Skin Cancer Globally from 1990 to 2019 and Its Predicted Level in 25\u2009Years. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09940-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ncomms1893","article-title":"Melanoma Induction by Ultraviolet A but Not Ultraviolet B Radiation Requires Melanin Pigment","volume":"3","author":"Noonan","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"842496","DOI":"10.3389\/fonc.2022.842496","article-title":"Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship","volume":"12","author":"Slominski","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"C1757","DOI":"10.1152\/ajpcell.00147.2022","article-title":"Neuroendocrine Signaling in the Skin with a Special Focus on the Epidermal Neuropeptides","volume":"323","author":"Slominski","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CMR.0b013e328322fc20","article-title":"Immunosuppression and Melanocyte Proliferation","volume":"19","author":"Zattra","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pathol-011110-130318","article-title":"The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs, and Skin","volume":"8","author":"Weaver","year":"2013","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse Events with IL-17 and IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis of Phase III Studies","volume":"34","author":"Loft","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bezzio, C., Vernero, M., Ribaldone, D.G., Alimenti, E., Manes, G., and Saibeni, S. (2023). Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15082197"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK Inhibitors and the Risk of Malignancy: A Meta-Analysis across Disease Indications","volume":"82","author":"Russell","year":"2023","journal-title":"Annu. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-Mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/14\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:40Z","timestamp":1760132380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/1\/14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ph17010014"],"URL":"https:\/\/doi.org\/10.3390\/ph17010014","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}